Clinical Trial Update: An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study [Phase 3]

View source ↗

Summary

Extension long-term study of tocilizumab (RoActemra/Actemra) in patients with polyarticular juvenile idiopathic arthritis who completed the WA19977 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED